Delcath Systems, Inc. (DCTH)
After hours:
| Previous Close | 10.65 |
| Open | 10.65 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 10.47 - 10.82 |
| 52 Week Range | 2.25 - 11.74 |
| Volume | |
| Avg. Volume | 310,576 |
| Market Cap | 313.049M |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.52 |
| Earnings Date | Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 |
- Business Wire
Delcath Systems to Host Third Quarter 2024 Earnings Call
QUEENSBURY, N.Y., October 25, 2024--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2024, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2024.
- Business Wire
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
QUEENSBURY, N.Y., October 17, 2024--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary revenue results for the third quarter of 2024, achieving $11.2 million, which included the recording of $10.0 million in U.S. revenue from the commercialization of HEPZATO KIT.
